Thursday, October 15, 2026

Luna Innovations Incorporated And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Luna Innovations Incorporated  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - Luna Innovations Incorporated (LUNA), Paylocity Holding Corporation (PCTY), KKR & Co. (KKR) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Luna Innovations Incorporated (LUNA)

54.7% sales growth and 5.67% return on equity

Luna Innovations Incorporated develops, manufactures, and markets fiber optic test, measurement, and control products worldwide.

Luna Innovations Incorporated's sales growth this year is anticipated to be 49.6% and 13.3% for next year.

Year-on-year quarterly revenue growth grew by 53.4%, now sitting on 91.84M for the twelve trailing months.

Volume

Today's last reported volume for Luna Innovations Incorporated is 8650 which is 94.19% below its average volume of 148752.

Luna Innovations Incorporated's sales growth for the next quarter is 54.7%. The company's growth estimates for the present quarter and the next is a negative 0% and negative -30.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.67%.

Volatility

Luna Innovations Incorporated's last day, last week, and last month's current volatility was 1.08%, 1.35%, and 2.56%, respectively.

Luna Innovations Incorporated's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.08% (day), 2.45% (last week), and 3.97% (last month), respectively.

Luna Innovations Incorporated's Stock Yearly Top and Bottom Value

Luna Innovations Incorporated's stock is valued at $10.19 at 17:22 EST, way under its 52-week high of $13.05 and way higher than its 52-week low of $5.26.

Luna Innovations Incorporated's Moving Average

Luna Innovations Incorporated's worth is below its 50-day moving average of $10.60 and below its 200-day moving average of $10.95.

2. Paylocity Holding Corporation (PCTY)

25.6% sales growth and 18.16% return on equity

Paylocity Holding Corporation provides cloud-based payroll and human capital management software solutions for medium-sized organizations in the United States.

Paylocity Holding Corporation's sales growth this year is expected to be 12.2% and 23% for next year.

Year-on-year quarterly revenue growth grew by 10.5%, now sitting on 584.36M for the twelve trailing months.

Volume

Today's last reported volume for Paylocity Holding Corporation is 83896 which is 57.07% below its average volume of 195415.

Paylocity Holding Corporation's sales growth for the next quarter is 25.6%. The company's growth estimates for the current quarter and the next is a negative 6.3% and negative -7.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.16%.

Volatility

Paylocity Holding Corporation's last day, last week, and last month's current volatility was 0.38%, 0.59%, and 1.76%, respectively.

Paylocity Holding Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.62% (day), 1.93% (last week), and 3.77% (last month), respectively.

Paylocity Holding Corporation's Stock Yearly Top and Bottom Value

Paylocity Holding Corporation's stock is valued at $191.89 at 17:22 EST, way under its 52-week high of $218.34 and way higher than its 52-week low of $124.75.

Paylocity Holding Corporation's Moving Average

Paylocity Holding Corporation's value is above its 50-day moving average of $182.86 and higher than its 200-day moving average of $186.43.

3. KKR & Co. (KKR)

19.1% sales growth and 36.38% return on equity

KKR & Co.'s sales growth this year is expected to be 30.6% and 15.3% for next year.

Year-on-year quarterly revenue growth declined by 0%, now sitting on 20.64B for the twelve trailing months.

Volume

Today's last reported volume for KKR & Co. is 1063560 which is 58.01% below its average volume of 2533170.

KKR & Co.'s sales growth for the next quarter is 19.1%. The company's growth estimates for the current quarter and the next is 100% and 56.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 36.38%.

Volatility

KKR & Co.'s last day, last week, and last month's current volatility was 0.15%, 1.38%, and 1.21%, respectively.

KKR & Co.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.73% (day), 2.31% (last week), and 1.97% (last month), respectively.

KKR & Co.'s Stock Yearly Top and Bottom Value

KKR & Co.'s stock is valued at $58.24 at 17:22 EST, under its 52-week high of $61.05 and way higher than its 52-week low of $32.73.

KKR & Co.'s Moving Average

KKR & Co.'s value is above its 50-day moving average of $57.11 and way higher than its 200-day moving average of $49.87.

Previous days news about KKR & Co.(KKR)

According to Business Wire on Friday, 16 July, "For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at www.kkr.com and on Twitter @KKR_Co."

4. Medical Properties Trust (MPW)

15.3% sales growth and 6.82% return on equity

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities.

Medical Properties Trust's sales growth this year is anticipated to be 20% and 7.3% for next year.

Year-on-year quarterly revenue growth grew by 24%, now sitting on 1.34B for the twelve trailing months.

Volume

Today's last reported volume for Medical Properties Trust is 3404690 which is 23.89% below its average volume of 4473510.

Medical Properties Trust's sales growth for the next quarter is 15.3%. The company's growth estimates for the ongoing quarter and the next is 33.3% and 24%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.82%.

Volatility

Medical Properties Trust's last day, last week, and last month's current volatility was 1.28%, 0.59%, and 0.96%, respectively.

Medical Properties Trust's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.19% (day), 1.58% (last week), and 1.98% (last month), respectively.

Medical Properties Trust's Stock Yearly Top and Bottom Value

Medical Properties Trust's stock is valued at $20.27 at 17:22 EST, way below its 52-week high of $22.82 and way higher than its 52-week low of $16.10.

Medical Properties Trust's Moving Average

Medical Properties Trust's value is below its 50-day moving average of $20.83 and below its 200-day moving average of $21.39.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com